Nakashima L - Search Results

1

Phase I/II trial of biweekly paclitaxel and cisplatin in the treatment of metastatic breast cancer.

Gelmon KA, O'Reilly SE, Tolcher AW, Campbell C, Bryce C, Ragaz J, Coppin C, Plenderleith IH, Ayers D, McDermott B, Nakashima L, Healey D, Onetto N. Gelmon KA, et al. Among authors: nakashima l. J Clin Oncol. 1996 Apr;14(4):1185-91. doi: 10.1200/JCO.1996.14.4.1185. J Clin Oncol. 1996. PMID: 8648373 Clinical Trial.

2

Guidelines for the optimal management of chemotherapy-induced nausea and vomiting: a consensus.

Osoba D, Warr DG, Fitch MI, Nakashima L, Warren B. Osoba D, et al. Among authors: nakashima l. Can J Oncol. 1995 Sep;5(3):381-400. Can J Oncol. 1995. PMID: 8853513

3

A phase I-II study of bi-weekly paclitaxel as first-line treatment in metastatic breast cancer.

Gelmon KA, Tolcher A, O'Reilly S, Campbell C, Bryce C, Shenkier T, Ragaz J, Ayers D, Nakashima L, Rielly S, Dulude H. Gelmon KA, et al. Among authors: nakashima l. Ann Oncol. 1998 Nov;9(11):1247-9. doi: 10.1023/a:1008445123416. Ann Oncol. 1998. PMID: 9862057 Free article. Clinical Trial.

4

Treatment of Kawasaki disease.

Nakashima L, Edwards DL. Nakashima L, et al. Clin Pharm. 1990 Oct;9(10):755-62. Clin Pharm. 1990. PMID: 2242655 Review.

5

A real-world data approach to determine the optimal dosing strategy for pembrolizumab.

Jang A, Nakashima L, Ng T, Fung M, Jiwani S, Schaff K, Suess J, Goncalves R, Jang D, Kuik K, Labelle S, Pow A. Jang A, et al. Among authors: nakashima l. J Oncol Pharm Pract. 2021 Apr;27(3):635-643. doi: 10.1177/1078155220929756. Epub 2020 Jun 15. J Oncol Pharm Pract. 2021. PMID: 32539663 Clinical Trial.

6

Utilization and toxicity patterns of 2-weekly (Q2W) versus 4-weekly (Q4W) nivolumab for treatment of adjuvant and metastatic melanoma at BC cancer.

Truong J, Yeung SST, Kletas V, de Lemos M, Schaff K, Nakashima L. Truong J, et al. Among authors: nakashima l. J Oncol Pharm Pract. 2024 Sep;30(6):1016-1022. doi: 10.1177/10781552231199048. Epub 2023 Sep 1. J Oncol Pharm Pract. 2024. PMID: 37654194

7

Evolution of cancer treatment and evolving challenges.

Nakashima L. Nakashima L. Healthc Manage Forum. 2018 Jan;31(1):26-28. doi: 10.1177/0840470417722568. Healthc Manage Forum. 2018. PMID: 29264971 Review.

8

Advising cancer patients on natural health products--a structured approach.

de Lemos ML, John L, Nakashima L, O'Brien RK, Taylor SC. de Lemos ML, et al. Among authors: nakashima l. Ann Pharmacother. 2004 Sep;38(9):1406-11. doi: 10.1345/aph.1E062. Epub 2004 Jul 13. Ann Pharmacother. 2004. PMID: 15252195

9

Barriers and facilitators for the safe handling of antineoplastic drugs.

Fazel SS, Keefe A, Shareef A, Palmer AL, Brenner DR, Nakashima L, Koehoorn MW, McLeod CB, Hall AL, Peters CE. Fazel SS, et al. Among authors: nakashima l. J Oncol Pharm Pract. 2022 Dec;28(8):1709-1721. doi: 10.1177/10781552211040176. Epub 2021 Oct 6. J Oncol Pharm Pract. 2022. PMID: 34612752 Review.

10

Real-world incidence of venetoclax toxicities in British Columbia.

Lee C, Markarian A, Ladha F, Nakashima L, de Lemos M, Schaff K, Woo S, Gerrie A. Lee C, et al. Among authors: nakashima l. J Oncol Pharm Pract. 2022 Jul;28(5):1163-1169. doi: 10.1177/10781552221084616. Epub 2022 Mar 7. J Oncol Pharm Pract. 2022. PMID: 35253497

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

17 results

Search Page

Filters